Boston Scientific Corp (BSX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 12-2024 | 12-2023 | 12-2022 | 12-2021 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 2,892,000 | 1,846,000 | 1,592,000 | 698,000 | 1,041,000 |
| Depreciation Amortization | 1,414,000 | 1,655,000 | 1,254,000 | 1,268,000 | 1,463,000 |
| Income taxes - deferred | -2,000 | -70,000 | -1,000 | -63,000 | -124,000 |
| Accounts receivable | -269,000 | -351,000 | -238,000 | -220,000 | -279,000 |
| Other Working Capital | -246,000 | -462,000 | -770,000 | -1,005,000 | -351,000 |
| Other Operating Activity | 745,000 | 817,000 | 666,000 | 848,000 | 120,000 |
| Operating Cash Flow | $4,534,000 | $3,435,000 | $2,503,000 | $1,526,000 | $1,870,000 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -876,000 | -790,000 | -711,000 | -576,000 | -540,000 |
| Net Acquisitions | -1,593,000 | -4,640,000 | -1,811,000 | -1,537,000 | -1,432,000 |
| Purchase Of Investment | -254,000 | -280,000 | -89,000 | -24,000 | 279,000 |
| Other Investing Activity | 83,000 | 23,000 | 37,000 | 126,000 | 96,000 |
| Investing Cash Flow | $-2,640,000 | $-5,687,000 | $-2,574,000 | $-2,011,000 | $-1,597,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -196,000 | 187,000 | -4,000 | -1,000 | N/A |
| Debt Issued | 1,558,000 | 2,145,000 | 0 | 3,270,000 | 0 |
| Debt Repayment | -258,000 | -25,000 | N/A | -3,184,000 | N/A |
| Common Stock Issued | 282,000 | 230,000 | 182,000 | 136,000 | 110,000 |
| Dividend Paid | N/A | N/A | N/A | -55,000 | -55,000 |
| Other Financing Activity | -1,781,000 | -723,000 | -173,000 | -714,000 | -150,000 |
| Financing Cash Flow | $-395,000 | $1,814,000 | $5,000 | $-548,000 | $-95,000 |
| Exchange Rate Effect | 42,000 | -11,000 | -4,000 | -9,000 | -6,000 |
| Beginning Cash Position | 606,000 | 1,055,000 | 1,126,000 | 2,168,000 | 1,995,000 |
| End Cash Position | 2,147,000 | 606,000 | 1,055,000 | 1,126,000 | 2,168,000 |
| Net Cash Flow | $1,541,000 | $-450,000 | $-70,000 | $-1,042,000 | $173,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 4,534,000 | 3,435,000 | 2,503,000 | 1,526,000 | 1,870,000 |
| Capital Expenditure | -876,000 | -790,000 | -711,000 | -588,000 | -554,000 |
| Free Cash Flow | 3,658,000 | 2,645,000 | 1,792,000 | 938,000 | 1,316,000 |